Monitor for any Form 4 filings or 13D amendments indicating warrant exercise and subsequent selling by stockholders. The overhang from potential resale could pressure the stock in the near term, but the actual impact depends on the pace of exercise and market conditions.
Price Chart
Executive Summary
SCYNEXIS filed an 8-K reporting shareholder approval to increase authorized common stock from 18.75M to 60M shares (post reverse-split), enabling the exercise of outstanding warrants held by selling stockholders. The filing also confirms the effectiveness of a previously filed S-3 registration statement covering up to 10.875M post-split shares for resale. This is a procedural step in the capital restructuring announced in March 2026, with no new financial disclosures or immediate fundraising.
Key Facts
- Authorized common stock increased from 18,750,000 to 60,000,000 shares (post-1-for-8 reverse split effective May 29, 2026).
- Shareholders approved the amendment at the June 25, 2026 Annual Meeting.
- Registration statement on Form S-3 (effective May 8, 2026) registers up to 10,875,000 post-split shares for resale by selling stockholders.
- Warrants (pre-funded and common) became exercisable upon the effectiveness of the authorized share increase on June 26, 2026.
- No new offering or additional capital raise; all shares registered are already issued or issuable upon existing warrants.
Financial Impact
Potential dilution of up to 10.875 million shares (post-split) upon warrant exercise, with corresponding cash proceeds to the company from warrant exercises (pre-funded warrants at $0.0001/share, common warrants at $9.60/share post-split). No immediate financial impact as no shares were sold in this filing.
Risk Factors
- Dilution from exercise of common warrants (5.4375M post-split shares at $9.60 exercise price) and pre-funded warrants (1.09375M shares).
- Selling pressure from stockholders registered for resale on the S-3.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001178253-26-000021 |
| Document: scyx-ex5_1.htm | 0001178253-26-000021 |
| Document: scyx-ex3_1.htm | 0001178253-26-000021 |
| Document: 0001178253-26-000021-index-headers.html | 0001178253-26-000021 |
| Document: 0001178253-26-000021-index.html | 0001178253-26-000021 |
| Document: 0001178253-26-000021.txt | 0001178253-26-000021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $5.12 (+8.94%) |
Jun 26, 2026 14w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $5.12 (+32.30%) |
May 22, 2026 19w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $5.12 (−6.02%) |
May 11, 2026 20w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $5.12 (+17.95%) |
Apr 20, 2026 23w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $5.12 (−39.62%) |
Mar 31, 2026 26w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $5.12 (−30.21%) |
Mar 4, 2026 30w ago | Press Release | $6.34 $7.12 | ▲ +12.34% | ▲ +14.58% | $5.12 (−19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access